Clinical Trial Update: Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds [Phase 3]

View source ↗

Summary

Phase 3 trial comparing immunogenicity and safety of GSK 134612 meningococcal vaccine to Mencevax ACWY in healthy adults 18-25; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• GSK 134612
• Mencevax ACWY

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-11-26